Speaking today (Tuesday 31 October) at the White Rose Bioscience Forum in York, Adams encourages companies to consider both their strengths and weaknesses, and to be open to all potential collaborations to ensure a healthy product portfolio.
“My advice is: be flexible, think out the box; what you can offer as company? Think about what you’ve got, be it technology or know how, and think hard about how you can capitalise on it. The whole company can contribute to this – talk to the research group and ask what else could we do with this technology, or put with this technology, and who could we talk to that they have contacts with? You’ll be surprised how many potential opportunities are generated from this creative brainstorming.”
This advice is based on Antisoma’s own experience. The company does not have a discovery arm; most of what it does is licensed directly from academia or from other biotechs, so it has to be creative in forging the right alliances to create a thriving product pipeline.
“Preclinically our focus is biology and we have enormous expertise in this area,” says Adams. This strength is very attractive to companies whose expertise lies on the chemistry side who have products that need biology.”
Since most cancer therapies around today are derived from plants, Antisoma was very interested to hear from a company contact about a young Australian company, Ecobiotics. Its expertise lay in its knowledge of the different chemical properties of Queensland rainforest plants at various stages of the plants’ growth. Says Adams: “Ecobiotics researchers knew how to select and synthesise the chemicals from various rainforest plants, but lacked the biological expertise, cancer models and in vitro capability.”
Antisoma and Ecobiotics now have a fruitful collaboration underpinned by a simple and transparent agreement.
“No money was exchanged up front and there are no unnecessary legal complexities. They provide us with molecules that display anti-cancer properties, we test them, and all resulting data is shared. Whilst Ecobiotics owns the IP, Antisoma has the right to select up to two molecule classes each year for development. All other test results on other molecules are owned by Ecobiotics which is free to develop the molecule further or offer it to other parties. It’s a perfect solution – they have the chemistry and we have the biology.
"I liken our networking approach to creating a spider’s web down whose strands products can come, whether developed in house, through collaborations or licensed in. The more strands you have the more chance you have of getting products to feed into your pipeline,” he says.
Jo Kelly | alfa
Microtechnology industry is hiring – positive developments of past years continue
09.04.2018 | IVAM Fachverband für Mikrotechnik
RWI/ISL-Container Throughput Index with minor decline on a high overall level
20.03.2018 | RWI – Leibniz-Institut für Wirtschaftsforschung
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...
A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.
The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...
Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.
Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...
A team of scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg investigated optically-induced superconductivity in the alkali-doped fulleride K3C60under high external pressures. This study allowed, on one hand, to uniquely assess the nature of the transient state as a superconducting phase. In addition, it unveiled the possibility to induce superconductivity in K3C60 at temperatures far above the -170 degrees Celsius hypothesized previously, and rather all the way to room temperature. The paper by Cantaluppi et al has been published in Nature Physics.
Unlike ordinary metals, superconductors have the unique capability of transporting electrical currents without any loss. Nowadays, their technological...
02.05.2018 | Event News
13.04.2018 | Event News
12.04.2018 | Event News
18.05.2018 | Power and Electrical Engineering
18.05.2018 | Information Technology
18.05.2018 | Information Technology